Ningbo Tianyi Medical Appliance (301097.SZ) has obtained the product registration certificate for "blood dialysis concentrate".
Tianyi Medical (301097.SZ) announced that its subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Tianyi Pharmaceutical") recently received the "Medical Device Registration Certificate" issued by the National Medical Products Administration, involving the product: "Hemodialysis Concentrate".
Ningbo Tianyi Medical Appliance (301097.SZ) announced that its subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Tianyi Pharmaceutical") recently received a "Medical Device Registration Certificate" issued by the National Medical Products Administration for their product "Blood Dialysis Concentrate Solution".
The blood dialysis concentrate solution, for which Tianyi Pharmaceutical obtained the medical device registration certificate this time, is composed of A concentrate solution (referred to as A solution) and online B powder (referred to as B powder). A solution is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder is composed of sodium bicarbonate. The A solutions are labeled as TR-YA3-01 and TR-YA3-02, with sizes of 5L per bucket and 10L per bucket. The B powder is labeled as TR-FB-LBT1, with a size of 650g per tube.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


